Department of Metabolic Disorders, Institute of Experimental Endocrinology, Biomedical Research Center SAS, Bratislava, Slovakia.
Laboratory for Study of Mitochondrial Disorders, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Orphanet J Rare Dis. 2023 Apr 24;18(1):92. doi: 10.1186/s13023-023-02689-3.
Pathogenic variants in the ATAD3A gene lead to a heterogenous clinical picture and severity ranging from recessive neonatal-lethal pontocerebellar hypoplasia through milder dominant Harel-Yoon syndrome up to, again, neonatal-lethal but dominant cardiomyopathy. The genetic diagnostics of ATAD3A-related disorders is also challenging due to three paralogous genes in the ATAD3 locus, making it a difficult target for both sequencing and CNV analyses.
Here we report four individuals from two families with compound heterozygous p.Leu77Val and exon 3-4 deletion in the ATAD3A gene. One of these patients was characterized as having combined OXPHOS deficiency based on decreased complex IV activities, decreased complex IV, I, and V holoenzyme content, as well as decreased levels of COX2 and ATP5A subunits and decreased rate of mitochondrial proteosynthesis. All four reported patients shared a strikingly similar clinical picture to a previously reported patient with the p.Leu77Val variant in combination with a null allele. They presented with a less severe course of the disease and a longer lifespan than in the case of biallelic loss-of-function variants. This consistency of the phenotype in otherwise clinically heterogenous disorder led us to the hypothesis that the severity of the phenotype could depend on the severity of variant impact. To follow this rationale, we reviewed the published cases and sorted the recessive variants according to their impact predicted by their type and the severity of the disease in the patients.
The clinical picture and severity of ATAD3A-related disorders are homogenous in patients sharing the same combinations of variants. This knowledge enables deduction of variant impact severity based on known cases and allows more accurate prognosis estimation, as well as a better understanding of the ATAD3A function.
ATAD3A 基因中的致病变体导致表型和严重程度的异质性,从隐性新生儿致死性桥脑小脑发育不良到更轻微的显性 Harel-Yoon 综合征,再到同样的新生儿致死性但显性心肌病。由于 ATAD3 基因座中的三个同源基因,ATAD3A 相关疾病的遗传诊断也具有挑战性,这使得它成为测序和 CNV 分析的困难目标。
我们在此报告了两个家系的四名复合杂合 p.Leu77Val 和 ATAD3A 基因外显子 3-4 缺失的个体。其中一名患者表现为 OXPHOS 缺陷的综合表现,基于降低的复合物 IV 活性、降低的复合物 IV、I 和 V 全酶含量以及 COX2 和 ATP5A 亚基的降低水平和降低的线粒体蛋白质合成率。所有四名报告的患者都与之前报道的携带 p.Leu77Val 变体与无功能等位基因的患者具有惊人相似的临床表型。他们的疾病进程较轻,寿命比双等位基因功能丧失变体长。这种表型在其他临床表现异质性的疾病中的一致性使我们假设表型的严重程度可能取决于变体影响的严重程度。为了遵循这一思路,我们回顾了已发表的病例,并根据患者的类型和疾病的严重程度对隐性变体进行了分类,以预测其变体影响的严重程度。
具有相同变体组合的 ATAD3A 相关疾病患者的临床表型和严重程度是同质的。这种知识使我们能够根据已知病例推断变体影响的严重程度,从而更准确地进行预后估计,并更好地理解 ATAD3A 的功能。